Humane Genomics, New York, NY, United States.
Humane Genomics, New York, NY, United States.
Int Rev Cell Mol Biol. 2023;379:241-261. doi: 10.1016/bs.ircmb.2023.03.004. Epub 2023 Apr 1.
Oncolytic virus therapy (OVT) is a promising modality that leverages the propensity of natural or engineered viruses to selectively replicate in and kill cancer cells. Over the past decade, (pre)clinical studies have focused on the development and testing of adenovirus, herpes simplex virus, and vaccinia virus-based vectors. These studies have identified barriers to success confronting the field. Here, we propose a set of selection criteria or ideal properties of a successful oncolytic virus, which include lack of pathogenicity, low seroprevalence, selectivity (infection and replication), transgene carrying capacity, and genome stability. We use these requirements to analyze the oncolytic virus landscape, and then identify a potentially optimal species for platform development - vesicular stomatitis virus.
溶瘤病毒治疗（OVT）是一种很有前途的治疗方法，它利用天然或工程病毒选择性复制和杀死癌细胞的倾向。在过去的十年中，（临床前）研究集中在开发和测试基于腺病毒、单纯疱疹病毒和牛痘病毒的载体。这些研究确定了该领域面临的成功障碍。在这里，我们提出了一套成功的溶瘤病毒的选择标准或理想特性，包括无致病性、低血清流行率、选择性（感染和复制）、转基因携带能力和基因组稳定性。我们使用这些要求来分析溶瘤病毒的现状，然后确定一种用于平台开发的潜在最佳病毒 - 水疱性口炎病毒。
